Alharbi Raed A, Pandha Hardev S, Simpson Guy R, Pettengell Ruth, Poterlowicz Krzysztof, Thompson Alexander, Harrington Kevin, El-Tanani Mohamed, Morgan Richard
Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Albaha University, Albaha, Saudi Arabia.
Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Oncotarget. 2017 Aug 7;8(52):89566-89579. doi: 10.18632/oncotarget.20023. eCollection 2017 Oct 27.
The HOX genes encode a family of transcription factors that have key roles in both development and malignancy. Disrupting the interaction between HOX proteins and their binding partner, PBX, has been shown to cause apoptotic cell death in a range of solid tumors. However, despite HOX proteins playing a particularly significant role in acute myeloid leukemia (AML), the relationship between HOX gene expression and patient survival has not been evaluated (with the exception of ), and the mechanism by which HOX/PBX inhibition induces cell death in this malignancy is not well understood. In this study, we show that the expression of , , , , and , but not in primary AML samples is significantly related to survival. Furthermore, the previously described inhibitor of HOX/PBX dimerization, HXR9, is cytotoxic to both AML-derived cell lines and primary AML cells from patients. The mechanism of cell death is not dependent on apoptosis but instead involves a regulated form of necrosis referred to as necroptosis. HXR9-induced necroptosis is enhanced by inhibitors of protein kinase C (PKC) signaling, and HXR9 combined with the PKC inhibitor Ro31 causes a significantly greater reduction in tumor growth compared to either reagent alone.
HOX基因编码一类转录因子,其在发育和恶性肿瘤中均发挥关键作用。已有研究表明,破坏HOX蛋白与其结合伴侣PBX之间的相互作用会导致一系列实体瘤发生凋亡性细胞死亡。然而,尽管HOX蛋白在急性髓系白血病(AML)中发挥着尤为重要的作用,但尚未评估HOX基因表达与患者生存率之间的关系(除外),且HOX/PBX抑制在这种恶性肿瘤中诱导细胞死亡的机制也尚未完全明确。在本研究中,我们发现,在原发性AML样本中, 、 、 、 和 的表达与生存率显著相关,而 的表达则不然。此外,先前描述的HOX/PBX二聚化抑制剂HXR9对AML来源的细胞系和患者的原发性AML细胞均具有细胞毒性。细胞死亡机制不依赖于凋亡,而是涉及一种称为坏死性凋亡的程序性坏死形式。蛋白激酶C(PKC)信号通路抑制剂可增强HXR9诱导的坏死性凋亡,与单独使用任一试剂相比,HXR9与PKC抑制剂Ro31联合使用可显著降低肿瘤生长。